The NIHR i4i Programme, in collaboration with the Office for Life Sciences (OLS), invites applications to the Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call. Proposals must demonstrate how the selected innovation will increase the proportion of cancers diagnosed at stages 1 and 2. Proposals aiming to directly address health inequalities in stage of cancer diagnosis are particularly sought.

The Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call is a one-stage call inviting applications for projects up to 36 months in duration, with no upper funding limit.

The call will be open to organisations which are UK legal entities, that have an innovative solution with the potential to increase the proportion of cancers diagnosed at stages 1 and 2. This call is open to small/medium commercial entities, NHS and Third Sector Service Providers, charitable organisations, local government bodies, as well as universities and research institutions.

For more information, and to apply, click here

Latest Opportunities

Exporting Starts Here programme for West Midlands companies

West Midlands Combined Authority (WMCA), funded by the UK Shared Prosperity Fund (UKSPF), has commissioned…

NIHR i4i Connect funding call

The NIHR Invention for Innovation (i4i) programme is accepting outline applications to their latest researcher-led Connect funding…

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

Latest News

Blog: Why cleanrooms are essential for medical-grade cannabis companies

By Medilink Midlands Member Airology Systems The demand for medical-grade cannabis has surged in recent…

Australia’s Cannim partners with PHTA to advance medicinal cannabis research

Leading medicinal cannabis company Cannim has announced its UK operations will be based at Birmingham’s…

New sleep trial shows dramatic benefits for participants

Cambridge Sleep Sciences (CSS), a leading UK innovator in sleep technology, has announced groundbreaking results…